Pharmacokinetics of novel atrial-selective antiarrhythmic agent vernakalant hydrochloride injection (RSD1235): influence of CYP2D6 expression and other factors.
about
Medication management of atrial fibrillation: emerging therapies for rhythm control and stroke prevention.Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I.The pharmaceutical pipeline for atrial fibrillation.Intravenous vernakalant: a review of its use in the management of recent-onset atrial fibrillation.Spotlight on intravenous vernakalant in recent-onset atrial fibrillation.Efficacy and safety of vernakalant in recent-onset atrial fibrillation after the European medicines agency approval: systematic review and meta-analysis.Clinical update on the management of atrial fibrillation.Vernakalant hydrochloride to treat atrial fibrillation.Intravenous vernakalant for the rapid conversion of recent onset atrial fibrillation: systematic review and meta-analysis.New anthyarrhythmic drugs for atrial fibrillation.Efficacy and Safety of Vernakalant for Cardioversion of Recent-onset Atrial Fibrillation in the Asia-Pacific Region: A Phase 3 Randomized Controlled Trial.Termination of Vernakalant-Resistant Atrial Fibrillation by Inhibition of Small-Conductance Ca2+-Activated K+ Channels in Pigs.Population pharmacokinetics of vernakalant hydrochloride injection (RSD1235) in patients with atrial fibrillation or atrial flutter.Efficacy and safety of intravenous vernakalant for the rapid conversion of recent-onset atrial fibrillation: A meta-analysis.
P2860
Q35209970-121EF3C5-F974-443F-903F-51E706CF1E05Q37611786-16D8C84F-54FE-44BF-865D-7156C8BDF478Q37821928-6AF92832-D4C7-468D-9E4F-4DC8A5AF1A1BQ37833065-15552BDD-A5DA-4E59-BD73-CD6BEAD623A5Q37884567-89674A3C-F77F-485F-A314-C6B91B3B46A2Q37968223-95A21BBB-7654-4479-BC13-2A0D8846F054Q38095871-2F32643C-9E54-4469-BEE8-ACC52410CA55Q38195102-7C99BC8A-8D55-47A7-8F87-F4D8CE240EB6Q38237297-7081B719-7557-42D9-A7BF-A62404EF021BQ38657316-BE3BFEF5-DD10-4997-B91F-8318CDFF5C7CQ41974132-6520E3EF-F60B-4475-9CCC-308A35EE054FQ42658517-A327462F-3ACF-45B4-8876-503B0482E5C7Q44963660-ABB843AC-1365-4BF1-B2C0-26C2E0BA5E0BQ48362682-26A33E73-D13E-439D-A522-1246F89E4154
P2860
Pharmacokinetics of novel atrial-selective antiarrhythmic agent vernakalant hydrochloride injection (RSD1235): influence of CYP2D6 expression and other factors.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
Pharmacokinetics of novel atri ...... expression and other factors.
@en
Pharmacokinetics of novel atri ...... kalant hydrochloride injection
@nl
type
label
Pharmacokinetics of novel atri ...... expression and other factors.
@en
Pharmacokinetics of novel atri ...... kalant hydrochloride injection
@nl
prefLabel
Pharmacokinetics of novel atri ...... expression and other factors.
@en
Pharmacokinetics of novel atri ...... kalant hydrochloride injection
@nl
P2093
P2860
P356
P1476
Pharmacokinetics of novel atri ...... expression and other factors.
@en
P2093
Gregory N Beatch
James Keirns
Jeffery J Wheeler
Lilian Clohs
Zhongping L Mao
P2860
P356
10.1177/0091270008325148
P577
2008-10-16T00:00:00Z